Stephan Gerlich, CEO,Bayer India - decisivechange for Bayer pharmacame only in 2005

摘要

The company said 67% of its local revenue comes from the crop science business. The chemicals segment contributes 26% and healthcare 5%."We want all of our subgroups in Indiato continue above their market growth," said Stephan Gerlich, head of Bayer in India.The healthcare unit, which has a joint venture with local drug maker Cadila Healthcare Ltd. for selling its pharmaceutical products, aims to be among the leading drug companies in India.